Fragment-based methods for the discovery of inhibitors modulating lysyl-tRNA synthetase and laminin receptor interaction
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Cho, Hye Young | - |
dc.contributor.author | Kim, Sunghoon | - |
dc.contributor.author | Jeon, Young Ho | - |
dc.date.accessioned | 2021-09-03T10:54:44Z | - |
dc.date.available | 2021-09-03T10:54:44Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-01-15 | - |
dc.identifier.issn | 1046-2023 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/84912 | - |
dc.description.abstract | Lysyl-tRNA synthetase (MRS) is an enzyme that conjugates lysine to its cognate tRNAs in the process of protein synthesis. In addition to its catalytic function, MRS binds to the 67-kDa laminin receptor (LR) on the cell membrane and facilitates cell migration and metastasis. Modulation of this interaction by small-molecule inhibitors can be exploited to suppress cancer metastasis. In this study, we present fragment-based methods for the identification of inhibitors and monitoring protein-protein interactions between KRS and LR. First, we identified the amino acid residues, located on the MRS anticodon-binding domain, which interact with the C-terminal extension of the LR. One-dimensional (1D) relaxation-edited nuclear magnetic resonance spectroscopy (NMR) and competition experiments were designed and optimized to screen the fragment library. For screening using two-dimensional (2D) NMR, we identified the indicative signals in the MRS anticodon-binding domain and selected inhibitors that bind to MRS and compete with LR at the MRS-LR binding interface. These methods may offer an efficient approach for the discovery of anti-metastatic drugs. (C) 2016 Published by Elsevier Inc. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | ACADEMIC PRESS INC ELSEVIER SCIENCE | - |
dc.subject | NMR-SPECTROSCOPY | - |
dc.subject | LIGAND-BINDING | - |
dc.subject | RELAXATION | - |
dc.subject | MACROMOLECULES | - |
dc.subject | CELLS | - |
dc.title | Fragment-based methods for the discovery of inhibitors modulating lysyl-tRNA synthetase and laminin receptor interaction | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Jeon, Young Ho | - |
dc.identifier.doi | 10.1016/j.ymeth.2016.10.009 | - |
dc.identifier.scopusid | 2-s2.0-85005808096 | - |
dc.identifier.wosid | 000393014400007 | - |
dc.identifier.bibliographicCitation | METHODS, v.113, pp.56 - 63 | - |
dc.relation.isPartOf | METHODS | - |
dc.citation.title | METHODS | - |
dc.citation.volume | 113 | - |
dc.citation.startPage | 56 | - |
dc.citation.endPage | 63 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemical Research Methods | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.subject.keywordPlus | NMR-SPECTROSCOPY | - |
dc.subject.keywordPlus | LIGAND-BINDING | - |
dc.subject.keywordPlus | RELAXATION | - |
dc.subject.keywordPlus | MACROMOLECULES | - |
dc.subject.keywordPlus | CELLS | - |
dc.subject.keywordAuthor | Lysyl-tRNA synthetase | - |
dc.subject.keywordAuthor | Laminin receptor | - |
dc.subject.keywordAuthor | Cancer metastasis | - |
dc.subject.keywordAuthor | Protein-protein interaction | - |
dc.subject.keywordAuthor | Fragment-based drug discovery | - |
dc.subject.keywordAuthor | Nuclear magnetic resonance (NMR) | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
145 Anam-ro, Seongbuk-gu, Seoul, 02841, Korea+82-2-3290-2963
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.